Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study

Postprandial metabolism is impaired in patients with type 2 diabetes (T2Dm). Two thiazolidinediones pioglitazone (PGZ) and rosiglitazone (RGZ) have similar effects on glycaemic control but differ in their effects on fasting lipids. This study investigated the effects of RGZ and PGZ on postprandial metabolism in a prospective, randomized crossover trial.

[1]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[2]  M. Egger,et al.  Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials , 2006, Current medical research and opinion.

[3]  G. Luc,et al.  The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients , 2006, Diabetologia.

[4]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[5]  H. Ginsberg,et al.  Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus , 2005 .

[6]  Alfonso T. Perez,et al.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.

[7]  R. DeFronzo,et al.  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. , 2004, Archives of internal medicine.

[8]  D. Sviridov,et al.  Physical Fitness and Reverse Cholesterol Transport , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[9]  M. Narce,et al.  Novel PPARgamma-dependent and independent effects for thiazolidinediones. , 2003, Current opinion in lipidology.

[10]  S. Deeb,et al.  Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. , 2003, Journal of lipid research.

[11]  M. Taskinen.  Diabetic dyslipidaemia: from basic research to clinical practice* , 2003, Diabetologia.

[12]  S. Wijmenga,et al.  Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. , 2003, Biochemistry.

[13]  S. Haffner.  Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. , 2002, The American journal of cardiology.

[14]  A. Ceriello,et al.  Evidence for an Independent and Cumulative Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Endothelial Dysfunction and Oxidative Stress Generation: Effects of Short- and Long-Term Simvastatin Treatment , 2002, Circulation.

[15]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[16]  J. S. St. Peter,et al.  A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.

[17]  J. Dekker,et al.  Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease , 2002, Diabetologia.

[18]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[19]  D. Illingworth,et al.  Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. , 2001, The American journal of cardiology.

[20]  C. Tack,et al.  Triglycerides and endothelial function in type 2 diabetes , 2001, European journal of clinical investigation.

[21]  Y. Momose,et al.  Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. , 2000, Biochemical and biophysical research communications.

[22]  Y. Iwamoto,et al.  Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. , 2000, Diabetes care.

[23]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[24]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[25]  C. Packard,et al.  Lipoprotein heterogeneity and apolipoprotein B metabolism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Taskinen,et al.  Metabolic basis of hypotriglyceridemic effects of insulin in normal men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[27]  A. Hermetter,et al.  New fluorogenic triacylglycerol analogs as substrates for the determination and chiral discrimination of lipase activities. , 1996, Journal of lipid research.

[28]  R. James,et al.  Differences in Lipoprotein Subfraction Composition and Distribution Between Type I Diabetic Men and Control Subjects , 1990, Diabetes.

[29]  S. Gidding,et al.  Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the National Cholesterol Education Program guidelines. , 1990, Archives of internal medicine.

[30]  M. Taskinen.  Lipoprotein lipase in diabetes. , 1987, Diabetes/metabolism reviews.

[31]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[32]  H. Ginsberg,et al.  Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. , 2005, The Journal of clinical investigation.

[33]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[34]  M. Taskinen,et al.  Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. , 1994, Journal of lipid research.